

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

**Case No. CBD1**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**MOLECULAR TAGGING SYSTEM**

the specification of which (check one) ☒ is attached hereto ☐ was filed on \_\_\_\_\_  
as U.S. application Serial No. \_\_\_\_\_ and amended on \_\_\_\_\_.

I hereby state and I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, section 1.56(a).

I hereby claim foreign priority benefit under Title 35, United States Code, section 119 of the foreign application(s) for patent listed below:

<u>Number</u>	<u>Country</u>	<u>Filing Date</u>	<u>Title</u>
---------------	----------------	--------------------	--------------

**NONE**

I hereby claim the benefit under Title 35, United States Code, section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
-------------------------------	--------------------	---------------

**NONE**

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

2

Stephen C. Macevicz

Reg. No. 30,285

Peter J. Dehlinger

Reg. No. 28,006

<b>SEND CORRESPONDENCE TO:</b>  <input checked="" type="checkbox"/> Stephen C. Macevicz <input type="checkbox"/> Peter J. Dehlinger  <u>21890 Rucker Drive</u> <u>Cupertino, CA 95014</u>	<b>DIRECT TELEPHONE CALLS TO:</b>  <input checked="" type="checkbox"/> Stephen C. Macevicz at (408) 252-4140  <input type="checkbox"/> Peter J. Dehlinger at (415) 324-0880  <b>Office Telefax: (510) 670-9302</b>
---	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of sole or first inventor: **Sydney Brenner**

Inventor's signature

*Sydney Brenner*

Date

*13 Oct 1994*

Residence:

*Cambridge, ENGLAND*

Citizenship:

**United Kingdom**

Post Office Address:

University of Cambridge, School of Clinical Medicine,  
 Level 5, Addenbrooke's Hospital,  
 Hills Road, Cambridge CB2QQ ENGLAND

Name of second inventor:

Inventor's signature

Date

Residence:

Citizenship:

Post Office Address:

Name of third inventor:

Inventor's signature

Date

Residence:

Citizenship:

Post Office Address:

Case No. CBD1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventors: Brenner

Patent No:

Serial No:

Issued:

Filed: 13 October 1994

Group Art Unit:

Title: MOLECULAR TAGGING SYSTEM

Examiner:

**DECLARATION CLAIMING SMALL ENTITY STATUS UNDER  
37 C.F.R. 1.9(f) and 1.27(c) (SMALL BUSINESS CONCERN)**

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified below:

**NAME OF CONCERN:** Lynx Therapeutics, Inc.

3832 Bay Center Place, Hayward, CA 94545

**ADDRESS OF CONCERN:** ~~485 Lincoln Center Drive, Foster City, California 94404~~

I hereby declare that the above identified small business concern qualifies as a small business concern qualifies as a small business concern as defined in 13 CRF 121.12, and reproduced in 37 CRF 1.9 (d) for purposes of paying reduced fees under Section 41 (a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly; one concern controls or has the power to control the other, or a third party or parties controls or has the power the control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled:

MOLECULAR TAGGING SYSTEM

described in the specification of the above-identified application and/or patent.

The rights held by the above identified small business concern are exclusive to it.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CRF 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Date: 13 October 1994

By:



TIM GEISER

Vice President

Lynx Therapeutics, Inc.